Name: Amplia Therapeutics (ATX) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

ATX

Pharmaceuticals, Biotechnology & Life Sciences

Amplia Therapeutics

Short interest: 0.01%; 0.00 pp 30d; as of 8 Oct 2026
Reported shorts: 30.1K
Shares on issue: 513.312M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Amplia Therapeutics

Amplia Therapeutics Limited focuses on developing therapies targeting focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. The company is positioned within the biotechnology sector, leveraging advanced scientific research to develop clinical candidates aimed at unmet medical needs, potentially offering transformative therapies in oncology and fibrotic diseases.

Company profile →

Amplia Therapeutics (ASX:ATX) has 0.01% of its shares on issue reported as short positions as of 8 Oct 2026, or about 30,144 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.23% in November 2024. ATX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads ATX today

Zanger BreakoutNot a candidate
CAN SLIMNot a candidate
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 15rank 946 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

ATX fundamentals

In the year to 31 Mar 2026, Amplia Therapeutics (ASX:ATX) recorded revenue of A$0 and a net loss after tax of A$7.7M. A year earlier it recorded revenue of A$0 and a net loss after tax of A$6.6M. Return on equity −25.5% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →